# Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/treatment-persistence-with-adalimumab-etanercept-or-infliximab-in-combination/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Boxiong Tang,Mirza I. Rahman,Heidi C. Waters,P. Callegari |
| Citations | 102 |
| DOI | 10.1016/s0149-2918(08)80063-x |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1983081844 |
| PMID | 18691998 |
| Type | article |
| Year | 2008 |

## Paper authors

- [Boxiong Tang](https://scholariq.org/researchers/boxiong-tang/)

## Paper journal

- [Clinical Therapeutics](https://scholariq.org/journals/clinical-therapeutics/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.